PT2637662T - Regime de doseamento para sedação com cns 7056 (remimazolam) - Google Patents

Regime de doseamento para sedação com cns 7056 (remimazolam)

Info

Publication number
PT2637662T
PT2637662T PT11794020T PT11794020T PT2637662T PT 2637662 T PT2637662 T PT 2637662T PT 11794020 T PT11794020 T PT 11794020T PT 11794020 T PT11794020 T PT 11794020T PT 2637662 T PT2637662 T PT 2637662T
Authority
PT
Portugal
Prior art keywords
remimazolam
seeding
cns
dosage scheme
dosage
Prior art date
Application number
PT11794020T
Other languages
English (en)
Inventor
Wilhelm-Ogunbiyi Karin
Borkett Keith
Tilbrook Gary Stuart
Wiltshire Hugh
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44907114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2637662(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of PT2637662T publication Critical patent/PT2637662T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT11794020T 2010-11-08 2011-11-07 Regime de doseamento para sedação com cns 7056 (remimazolam) PT2637662T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10014366 2010-11-08
EP10014784 2010-11-19
EP10014819 2010-11-22
EP10014972A EP2450039A1 (en) 2010-11-08 2010-11-25 Dosing regimen for sedation with CNS 7056 (Remimazolam)

Publications (1)

Publication Number Publication Date
PT2637662T true PT2637662T (pt) 2019-03-25

Family

ID=44907114

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11794020T PT2637662T (pt) 2010-11-08 2011-11-07 Regime de doseamento para sedação com cns 7056 (remimazolam)

Country Status (17)

Country Link
US (10) US9561236B2 (pt)
EP (3) EP2450039A1 (pt)
JP (1) JP6084571B2 (pt)
KR (1) KR102059399B1 (pt)
CN (1) CN103347519B (pt)
AU (1) AU2011328497B8 (pt)
DK (1) DK2637662T3 (pt)
EA (1) EA024926B1 (pt)
ES (1) ES2715179T3 (pt)
HR (1) HRP20190447T1 (pt)
HU (1) HUE044095T2 (pt)
LT (1) LT2637662T (pt)
PL (1) PL2637662T3 (pt)
PT (1) PT2637662T (pt)
RS (1) RS58577B1 (pt)
SI (1) SI2637662T1 (pt)
WO (1) WO2012062439A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168010A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of severe pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
PE20150683A1 (es) * 2012-05-22 2015-06-03 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de accion corta
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
AU2013309860B2 (en) 2012-08-31 2017-12-21 Paion Uk Limited Method for administering hypnotic/sedative agent
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103232454A (zh) * 2013-05-05 2013-08-07 王元青 治疗精神疾病的药物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016011943A1 (zh) * 2014-07-23 2016-01-28 李勤耕 新的苯并二氮杂䓬类衍生物及其用途
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
WO2017013677A1 (en) 2015-07-18 2017-01-26 Neon Laboratories Limited Stable liquid injectable solution of midazolam and pentazocine
US10821087B2 (en) 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
US20190175613A1 (en) * 2016-04-14 2019-06-13 Paion Uk Limited Orally inhaled and nasal benzodiazepines
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
CN108143733B (zh) * 2017-12-15 2020-12-25 宜昌人福药业有限责任公司 一种麻醉镇痛药物组合物及其制备方法
CN111712501A (zh) * 2018-02-13 2020-09-25 江苏恩华络康药物研发有限公司 苯二氮卓衍生物盐酸盐与晶型、制备方法及其应用
EP3714884A1 (en) * 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN112402428B (zh) * 2020-11-26 2022-02-25 李依泽 瑞马唑仑在制备治疗阿片类药物诱发的术后痛觉过敏的药物中的应用
CN114903904B (zh) * 2021-02-08 2024-02-09 宜昌人福药业有限责任公司 瑞马唑仑药用盐和阿片样物质的注射用药物组合物
CN116270659A (zh) * 2023-01-13 2023-06-23 上海市胸科医院 瑞马唑仑在制备治疗、减缓或处理骨癌疼痛的产品中的用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
BR6915069D0 (pt) 1969-02-28 1973-08-16 Upjohn Co Compostos organicos e processo
NL7012813A (pt) 1969-09-01 1971-03-03
DE2156472A1 (de) 1970-11-23 1972-05-31 Ciba-Geigy Ag, Basel (Schweiz) Verfahren zur Herstellung von neuen Diazepinderivaten
US3933794A (en) 1971-08-04 1976-01-20 The Upjohn Company 2-(2-Alkynylamino)-3H-1,4-benzodiazepines
FR2183716A1 (en) 1972-05-05 1973-12-21 Centre Etd Ind Pharma Substd-6-phenyl-4h-imidazo (1,2-a)-1,4-benzo diazepines - - tranquillisers anxiolytics,sedatives and muscle-relaxants
IE41197B1 (en) 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
CH608234A5 (en) 1974-08-30 1978-12-29 Crc Ricerca Chim Process for the preparation of lithium salts of 1,4-benzodiazepines
DE2900017A1 (de) 1978-01-10 1979-07-12 Clin Midy 3-alkoxycarbonyl-benzodiazepin- derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
MC1528A1 (fr) 1982-07-21 1984-04-13 Hoffmann La Roche Imidazobenzodiazepines
IT1165588B (it) 1983-03-23 1987-04-22 Medosan Ind Biochimi 1,4 benzodiazepine terapeuticamente attive
US4724237A (en) 1984-06-26 1988-02-09 Merck & Co., Inc. 2-substituted-aminomethyl-1,4-benzodiazepines
US4755508A (en) 1984-06-26 1988-07-05 Merck & Co., Inc. Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
CA1332410C (en) 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ES2084577T3 (es) 1986-10-24 1996-05-16 Abbott Lab Ensayo, trazadores, inmunogenos y anticuerpos para benzodiazepinas.
WO1989010127A1 (en) 1988-04-29 1989-11-02 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
DK0411668T4 (da) 1989-08-04 1999-08-09 Merck Sharp & Dohme Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
DK0450097T3 (da) 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
CA2032427A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
IL96613A0 (en) 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
EP0523845A3 (en) 1991-06-14 1993-11-18 Merck & Co Inc New benzodiazepine analogs
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
US5834464A (en) 1994-11-18 1998-11-10 Merck & Co., Inc. Imidazolinobenzodiazepines
DK0801651T3 (da) 1995-01-06 2001-10-22 Hoffmann La Roche Hydroxymethyl-imidazodiazepiner og deres estere
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
AU722110B2 (en) 1996-06-28 2000-07-20 Merck & Co., Inc. Pharmaceutical preparation
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP0881235A1 (fr) 1997-05-26 1998-12-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux ylures de phosphore, leur préparation et leurs utilisations notamment en tant que bases fortes faiblement nucléophiles
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
EP1161949A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1479666A4 (en) 2002-02-28 2010-10-13 Japan Tobacco Inc ESTER CONNECTION AND THEIR MEDICAL USE
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
SI21850A (sl) 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
JP2008526984A (ja) 2005-01-18 2008-07-24 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
KR20070112164A (ko) 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
US20070040501A1 (en) 2005-08-18 2007-02-22 Aitken Bruce G Method for inhibiting oxygen and moisture degradation of a device and the resulting device
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
GB0613692D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
HUE032273T2 (en) 2007-05-22 2017-09-28 Chemocentryx Inc 3-Imidazolyl-pyrazolo [3,4-b] pyridines
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
EP2346506A1 (en) 2008-10-16 2011-07-27 Paion UK Limited Administration scheme of polar opioid metabolites for post-operative pain management
JP4669584B2 (ja) 2009-03-30 2011-04-13 日本製紙株式会社 Ｎ−オキシル化合物の回収・再利用方法
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
JP5635275B2 (ja) 2010-01-28 2014-12-03 日清紡ホールディングス株式会社 アルコールの酸化方法
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
JP5585597B2 (ja) 2012-01-27 2014-09-10 株式会社デンソー 車輪位置検出装置およびそれを備えたタイヤ空気圧検出装置
PE20150683A1 (es) 2012-05-22 2015-06-03 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de accion corta
AU2013309860B2 (en) 2012-08-31 2017-12-21 Paion Uk Limited Method for administering hypnotic/sedative agent
BR112015007031B1 (pt) 2012-09-28 2018-08-07 Huawei Technologies Co., Ltd. Método de processamento de processo de informação de estado de canal, dispositivo de rede e equipamento de usuário
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión

Also Published As

Publication number Publication date
HRP20190447T1 (hr) 2019-05-03
US20180318316A1 (en) 2018-11-08
SI2637662T1 (sl) 2019-05-31
US10722522B2 (en) 2020-07-28
EA024926B1 (ru) 2016-11-30
EP2637662A1 (en) 2013-09-18
US9827251B1 (en) 2017-11-28
US20250360144A1 (en) 2025-11-27
US20140080815A1 (en) 2014-03-20
AU2011328497B8 (en) 2015-04-16
US12201637B2 (en) 2025-01-21
KR102059399B1 (ko) 2019-12-26
AU2011328497A1 (en) 2013-04-18
RS58577B1 (sr) 2019-05-31
AU2011328497A8 (en) 2015-04-16
US20200316088A1 (en) 2020-10-08
PL2637662T3 (pl) 2019-06-28
CN103347519B (zh) 2016-05-18
US20200171046A1 (en) 2020-06-04
KR20140000702A (ko) 2014-01-03
US20230346796A1 (en) 2023-11-02
US10195210B2 (en) 2019-02-05
EP2637662B1 (en) 2019-01-09
ES2715179T3 (es) 2019-06-03
WO2012062439A1 (en) 2012-05-18
US20190111062A1 (en) 2019-04-18
US20170112852A1 (en) 2017-04-27
JP2013541567A (ja) 2013-11-14
US9737547B2 (en) 2017-08-22
AU2011328497B2 (en) 2015-03-12
JP6084571B2 (ja) 2017-02-22
HUE044095T2 (hu) 2019-09-30
CN103347519A (zh) 2013-10-09
EA201390672A1 (ru) 2013-11-29
EP2450039A1 (en) 2012-05-09
DK2637662T3 (en) 2019-04-08
LT2637662T (lt) 2019-04-10
EP3492080A1 (en) 2019-06-05
US20180042939A1 (en) 2018-02-15
US10052334B2 (en) 2018-08-21
US10342800B2 (en) 2019-07-09
US9561236B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
PT2637662T (pt) Regime de doseamento para sedação com cns 7056 (remimazolam)
SMT201600350B (it) Composizioni farmaceutiche
SMT201700008B (it) Composizione farmaceutica
GB201206690D0 (en) X-System 2
EP2635228A4 (en) CLEAN DISPENSER
EP3581721C0 (en) WEAR ARRANGEMENT
BR112014003052A2 (pt) composições farmacêuticas
EP2783052A4 (en) VERSCHLEISSANORDNUNG
IT1394860B1 (it) Composti farmaceutici
DK3246018T3 (da) Farmaceutisk sammensætning
CO6930367A2 (es) Composiciones farmaceúticas
GT201200303A (es) Formulaciones farmacéuticas
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
EE201300005A (et) Ravimkoostis
HUE040370T2 (hu) Gyógyszerkészítmények
BRPI1015368A2 (pt) distribuidor de produto
CO6801722A2 (es) Composiciones farmacéuticas
EP2753311A4 (en) ANTIOXIDATIVE FORMULATIONS
IT1393930B1 (it) Composti farmaceutici
SMT201200040B (it) Composizioni di flupentixol
FR2965705B1 (fr) Compositions d'edulcorants
ME02908B (me) Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije
EP2628733A4 (en) ACYLBENZEN DERIVATIVE
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
IT1395724B1 (it) Composti farmaceutici